Sonnet BioTherapeutics (SONN) Prices 35.3M Share+Warrant Offering at $0.85/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering
August 19, 2021 9:38 PM EDTPRINCETON, NJ / ACCESSWIRE / August 19, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, today announced the pricing of an underwritten public offering of 35,294,117 shares of common stock or common stock equivalents (which includes pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 35,294,117 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold... More
